Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| BIIB | Biogen Inc. | 1.31% | 353.03 | 1.2% | $871.11m | |
| AMGN | Amgen Inc. | -0.53% | 194.88 | 1.2% | $564.77m | |
| CELG | Celgene Corporation | -0.54% | 85.23 | 1.2% | $555.79m | |
| GILD | Gilead Sciences, Inc. | -0.16% | 77.26 | 0.9% | $499.41m | |
| SRPT | Sarepta Therapeutics, Inc. | -1.97% | 136.68 | 16.6% | $376.94m | |
| VRTX | Vertex Pharmaceuticals Incorporated | 0.40% | 181.22 | 1.9% | $331.68m | |
| REGN | Regeneron Pharmaceuticals, Inc. | -0.79% | 364.75 | 2.6% | $305.25m | |
| ILMN | Illumina, Inc. | -1.63% | 301.99 | 3.5% | $267.19m | |
| BLUE | Bluebird Bio, Inc. | -1.83% | 177.30 | 15.7% | $219.07m | |
| NKTR | Nektar Therapeutics | 0.00% | 47.79 | 5.6% | $188.00m | |
| ALXN | Alexion Pharmaceuticals, Inc. | -0.95% | 134.58 | 2.0% | $175.68m | |
| FMI | Foundation Medicine, Inc. | 0.00% | 136.70 | 8.8% | $168.36m | |
| EXAS | Exact Sciences Corporation | 1.41% | 64.66 | 25.4% | $159.06m | |
| BMRN | BioMarin Pharmaceutical Inc. | -0.85% | 102.73 | 4.4% | $138.72m | |
| EXEL | Exelixis, Inc. | -3.61% | 21.07 | 6.4% | $137.74m |
Company Profile
TRACON Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on the development and commercialization of novel targeted therapeutics for cancer, age-related macular degeneration and fibrotic diseases. The company products include TRC105, is an anti-endoglin antibody that is being developed for the treatment of multiple solid tumor types, TRC205 an anti-endoglin antibody that is in preclinical development for the treatment of fibrotic diseases and TRC102, a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma. TRACON Pharmaceuticals was founded in October 2004 and is headquartered in San Diego, CA.